Key Points
- Guardant Health CEO Amirali Talasaz sold 50,000 shares on May 12 at an average price of $100.32, totaling about $5.02 million. The sale reduced his ownership by 2.33% and was made under a pre-arranged Rule 10b5-1 trading plan.
- Shares of GH were trading down about 1.5% and opened at $98.47. The stock has ranged from a 12-month low of $36.36 to a high of $120.74.
- Guardant Health recently reported strong revenue growth of 39.4% year over year to $281.27 million, though it missed EPS estimates. Analysts remain mostly bullish, with a consensus rating of Moderate Buy and an average price target of $129.42.
Guardant Health, Inc. (NASDAQ:GH - Get Free Report) CEO Amirali Talasaz sold 50,000 shares of the business's stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $100.32, for a total transaction of $5,016,000.00. Following the completion of the sale, the chief executive officer owned 2,096,504 shares in the company, valued at approximately $210,321,281.28. This trade represents a 2.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Guardant Health Trading Down 1.5%
Shares of GH opened at $98.47 on Thursday. The firm has a market cap of $13.06 billion, a P/E ratio of -29.05 and a beta of 1.48. Guardant Health, Inc. has a 12-month low of $36.36 and a 12-month high of $120.74. The company's 50-day moving average price is $89.16 and its 200 day moving average price is $97.74.
Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings data on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The company had revenue of $281.27 million for the quarter, compared to analysts' expectations of $269.74 million. The company's revenue for the quarter was up 39.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.62) EPS. Equities research analysts forecast that Guardant Health, Inc. will post -2.87 earnings per share for the current year.
Hedge Funds Weigh In On Guardant Health
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. V Square Quantitative Management LLC acquired a new position in Guardant Health in the fourth quarter valued at approximately $27,000. Chesapeake Asset Management LLC purchased a new stake in Guardant Health in the fourth quarter valued at approximately $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in Guardant Health in the fourth quarter valued at approximately $31,000. Elyxium Wealth LLC purchased a new stake in Guardant Health in the fourth quarter valued at approximately $35,000. Finally, Parallel Advisors LLC lifted its stake in Guardant Health by 164.7% in the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company's stock valued at $36,000 after buying an additional 219 shares during the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of equities analysts have recently commented on GH shares. Robert W. Baird started coverage on Guardant Health in a research report on Tuesday, February 17th. They set an "outperform" rating and a $120.00 price objective for the company. Leerink Partners boosted their price objective on Guardant Health from $170.00 to $180.00 and gave the stock an "outperform" rating in a research report on Friday, February 20th. UBS Group reissued a "buy" rating and set a $175.00 price objective on shares of Guardant Health in a research report on Friday, January 30th. Weiss Ratings reissued a "sell (d-)" rating on shares of Guardant Health in a research report on Tuesday, April 21st. Finally, Canaccord Genuity Group boosted their price objective on Guardant Health from $125.00 to $135.00 and gave the stock a "buy" rating in a research report on Friday, February 20th. Nineteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $129.42.
Check Out Our Latest Report on Guardant Health
Guardant Health Company Profile
(
Get Free Report)
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
